GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of “Hold” by Analysts

Shares of GSK PLC Sponsored ADR (NYSE:GSK) have earned a consensus recommendation of “Hold” from the ten brokerages that are currently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price target among analysts that have covered the stock in the last year is $53.00.

Several analysts recently issued reports on the stock. Wall Street Zen raised shares of GSK from a “hold” rating to a “buy” rating in a report on Saturday, June 27th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of GSK in a report on Thursday, July 9th. Weiss Ratings lowered shares of GSK from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, June 11th. Royal Bank Of Canada restated an “outperform” rating on shares of GSK in a report on Tuesday, June 9th. Finally, HSBC raised GSK from a “reduce” rating to a “hold” rating in a research report on Monday, July 6th.

GSK News Summary

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Jefferies resumed coverage on GSK with a Buy rating and a price target implying roughly 30% upside, arguing recent business-development deals strengthen the company’s long-term revenue outlook. Article Title
• Neutral Sentiment: GSK said camlipixant will still continue in a separate Phase 2b study for irritable bowel syndrome, leaving some optionality for the drug despite the cough-program setback. Article Title
• Negative Sentiment: GSK halted further development of camlipixant for refractory chronic cough after the Phase 3 program missed a main efficacy goal, a setback that may reduce confidence in the company’s respiratory pipeline. Article Title

GSK Trading Down 1.8%

NYSE:GSK opened at $51.81 on Friday. GSK has a 12 month low of $36.16 and a 12 month high of $61.69. The firm has a market cap of $104.79 billion, a price-to-earnings ratio of 13.46, a P/E/G ratio of 3.31 and a beta of 0.35. The company has a quick ratio of 0.52, a current ratio of 0.79 and a debt-to-equity ratio of 0.80. The company’s 50 day moving average is $51.55 and its 200-day moving average is $53.34.

GSK Cuts Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, July 9th. Shareholders of record on Friday, May 15th were issued a $0.44 dividend. The ex-dividend date of this dividend was Friday, May 15th. This represents a $1.76 dividend on an annualized basis and a yield of 3.4%. GSK’s dividend payout ratio (DPR) is 46.49%.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in GSK. First Horizon Corp boosted its position in shares of GSK by 78.7% in the fourth quarter. First Horizon Corp now owns 536 shares of the pharmaceutical company’s stock valued at $26,000 after acquiring an additional 236 shares during the period. Elyxium Wealth LLC bought a new position in GSK during the fourth quarter worth $30,000. Triumph Capital Management acquired a new position in GSK during the 3rd quarter valued at $40,000. 1248 Management LLC raised its stake in GSK by 314.6% during the 3rd quarter. 1248 Management LLC now owns 1,053 shares of the pharmaceutical company’s stock valued at $46,000 after purchasing an additional 799 shares during the last quarter. Finally, Coston McIsaac & Partners boosted its holdings in GSK by 17.3% in the 4th quarter. Coston McIsaac & Partners now owns 1,395 shares of the pharmaceutical company’s stock valued at $68,000 after purchasing an additional 206 shares during the period. 15.74% of the stock is owned by institutional investors.

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.